Ask consumers whether they’d prefer to apply sunscreen, pain relief, or acne treatment with a pump or a continuous spray can, and most will choose the can. The reason is simple: continuous spray doesn’t get on your hands, and you can apply it exactly where you want — behind your back, on a child, across a large body surface — without effort or mess.
That consumer preference is the business case. Brands that introduce a continuous spray version of an existing product see compressed repurchase cycles — not because the format wastes product, but because consumers actually use it. As Vahid Kasliwala of InSpec Solutions puts it: “The usage rate is higher because of satisfaction. Customers love it so much they use it up quicker.” Compared to a pump that gets abandoned partway through the bottle, a continuous spray can actually gets finished — and reordered.
If you’re evaluating whether spray makes sense for your line, this post covers the full picture: why brands are adding the format, which categories translate well, what actually changes in formulation, and what to expect from a manufacturer in terms of MOQs, timelines, and realistic entry requirements.
Why Brands Are Expanding Into Spray
The consumer preference argument starts with the pump sprayer. Sustained pressing fatigues the hand, output is uneven, and bottles rarely get used to the last drop. A continuous spray can — technically a bag-on-valve (BOV) system — delivers consistent coverage with one press, no hand effort.
Vahid Kasliwala puts it directly: “People used to use the finger sprayers and people’s fingers get tired. Consumers really like a can that can be sprayed.”
Beyond finger fatigue, there’s a reach problem. Back application — relevant for SPF, pain relief, and several OTC categories — is difficult with a lotion or pump. You can’t effectively rub lotion onto your own back. As Vahid frames it: “If you want to spray your back, it’s hard to rub lotion on your back. You could spray it because you just get it behind you.” Non-contact application is also a practical hygiene argument in acne, antifungal, and hemorrhoid categories: no bacteria transfer from hand to skin.
The prestige argument is real. Continuous spray is a format with a genuine barrier to entry. The manufacturing universe that can produce a pump or lotion in a bottle is enormous — thousands of contract manufacturers. The universe that can produce a BOV continuous spray is roughly 50. That’s not a marketing claim; it’s a function of the specialized equipment, pressurized fill lines, and formulation expertise required. When a brand invests in developing a spray SKU and backs it with marketing spend, a knockoff competitor can’t easily replicate it overnight. That manufacturing complexity protects the brand’s investment.
The price premium follows. A product that retails for $2 in a bottle or tube typically commands $3 to $4 in a continuous spray format. The format isn’t just more convenient — it’s perceived as more sophisticated, and the market prices it accordingly.
Which Product Categories Translate Best to Continuous Spray
Not every cream or lotion makes a viable spray. The categories with proven consumer demand in continuous spray formats share a few common traits: targeted delivery benefits, non-contact application logic, and body coverage that hand application complicates. OTC actives in particular have strong category fit — the spray format doubles as a clinical delivery mechanism, not just a packaging preference.
US search interest confirms the trend. Over the past five years, Google searches for “acne spray” are up 381%, “acne body spray” up 437%, “lidocaine spray” up 105%, and “hemorrhoid spray” up 144%. (Google Trends, US, April 2021–March 2026.) These aren’t niche searches — they reflect consumer demand that’s actively forming and that brands in these categories are already chasing.
Categories with established demand and where InSpec manufactures:
- SPF / Sunscreen — The highest-volume continuous spray category by a significant margin. The spray sunscreen market was valued at USD 2.8 billion in 2024 and is projected to reach USD 5.1 billion by 2033, at a 7.5% CAGR. (Verified Market Reports) The aerosol spray segment holds 45% of that market. Full-body coverage, back application, and no white cast from hand-rubbing are the consumer drivers. Coppertone pioneered the format; store brands and private label manufacturers followed. (bagonvalve.com)
- Pain relief (menthol, lidocaine, camphor) — Targeted application keeps the active where you want it. As Vahid puts it: “If you have a menthol, you don’t want your whole body to smell. You can just spray it on and where it hits is where it hits.”
- Acne treatment — Non-contact delivery is the hygiene argument: spray toners and spot treatments with OTC actives (salicylic acid, benzoyl peroxide) avoid transferring bacteria from hands to active breakouts.
- Antifungal — Targeted, non-contact delivery for foot, nail, and groin applications where cream application is awkward. OTC monograph category — manufacturing requirements apply.
- Hemorrhoid sprays — A category with specific continuous spray demand and a confirmed private label gap at major retailers, including Walgreens. InSpec manufactures in this category.
If the product’s benefit story requires rubbing in or depends on tactile application, spray probably isn’t the right format. If reach, contact avoidance, or targeted delivery is part of how the product works — the category case is real.
What Changes When You Move From Cream or Lotion to Spray
This is the section most brands underestimate. Moving to continuous spray is not a packaging decision — it’s a formulation project. Your existing cream doesn’t go “into a can.” It gets reformulated for a different delivery system.
Formulation Has to Be Reworked, Not Repackaged
Viscosity is the first gate. Continuous spray requires a formula that flows through a valve stem and atomizes correctly. Heavy creams and gels fail this without significant adaptation. A formula that performs well in a tube may be completely non-functional in a pressurized spray system. (bagonvalve.com, Signature Filling Company)
Propellant architecture is different from what most brands expect. In a bag-on-valve system, the formula lives inside a sealed bag; the propellant (typically compressed nitrogen or air) sits between the bag and the can wall — the two never touch. This is what enables 360° spray and formula purity. But the formula still must be stable in a sealed, pressurized environment, and testing is required. (Signature Filling Company)
Bag material compatibility is a required check. BOV bags use multi-layer laminated aluminum. Certain formulation chemistries — pH levels, specific actives, reactive compounds — can interact with bag materials. This is a testing step, not an optional one. (Signature Filling Company)
Active ingredient behavior changes in spray delivery. Zinc oxide in SPF, benzoyl peroxide in acne, menthol or lidocaine in pain relief — each carries its own stability and compatibility profile in a pressurized spray environment. This is not a “copy the lotion formula into a can” exercise.
Valve selection affects the end product. Coverage, droplet size, and spray angle are determined partly by valve selection, not just the formula. This is a co-development decision — not something the brand specifies unilaterally.
Products requiring shaking before use are not suitable for continuous spray systems. (bagonvalve.com)
The brands that move through formulation fastest are the ones who arrive with a defined formula (even one that needs adaptation), a target fill volume, and clarity on regulatory classification — cosmetic or OTC drug product. A formulation feasibility conversation at the outset typically resolves these questions quickly and prevents surprises later in development.
What to Expect From a Manufacturer — MOQs, Timelines, and What “Higher Barrier to Entry” Actually Means
Continuous spray filling requires specialized pressurized production lines. Not every contract manufacturer runs them — the capability represents real capital investment and operational complexity. When Vahid Kasliwala describes continuous spray as “a prestige product” with “a higher barrier to entry,” that’s the operational reality, not marketing framing.
MOQs are higher than tubes or bottles — and that’s the right framing. This isn’t a reason to avoid the format; it’s a qualifier for brand readiness. InSpec’s minimum order quantity for continuous spray is 10,000 units. Brands that succeed with continuous spray typically arrive with demand signals already established: retailer interest, proven repurchase on an existing format, or volume projections that justify the commitment. Spray rewards brands who’ve done the market work first.
Timeline from inquiry to first production run depends on formulation path. For brands using a stock formula with minimal adaptation, 90 days from inquiry to first run is realistic when everything lines up. For a tech transfer — bringing an existing brand formula and adapting it for the BOV system — the path runs 90 to 180 days, accounting for formulation adaptation, stability testing, valve selection, and production scheduling. Brands in seasonal categories (SPF being the obvious one) need to initiate significantly earlier than they’d expect.
What to bring to the first conversation. A defined formula (even one that needs work), a target fill volume, a packaging concept, and clarity on regulatory classification. “We want a spray” is a starting point for a longer process, not a quote trigger.
Is a Spray SKU the Right Move for Your Brand Right Now?
A few signals that suggest spray is worth pursuing:
- Existing brand in SPF, pain relief, acne, antifungal, or OTC personal care
- Consumer use case involves body coverage, reach, or non-contact application
- Demand signals exist: retailer interest, search volume, proven repurchase on your current format
- Volume projections that support 10,000-unit MOQ thresholds
If you’re already running a pump sprayer, a continuous spray conversion is a format upgrade — and formulation adaptation is typically less significant than converting from a cream or lotion.
The harder case is an early-stage brand without established distribution or proven demand. Higher MOQs make continuous spray a difficult first SKU. The sequence question matters: build the base product, prove demand, then expand into spray.
If the category fits and the demand signals are there, the first step isn’t a quote request — it’s a formulation feasibility conversation.
InSpec Solutions manufactures continuous sprays across SPF, OTC, and personal care categories using bag-on-valve technology, with capacity available. The first conversation is a feasibility discussion, not a price negotiation. If you’re evaluating whether a spray format is right for your line, we can tell you quickly whether InSpec is a fit and what the formulation path looks like.
How BOV technology works → InSpec spray manufacturing capabilities →
